Oxytocin

3

Review clinical trials related to Oxytocin. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Oxytocin for Weight Loss in Adolescents

This is a randomized, double blind, placebo-controlled study of the effects of intranasal oxytocin in youths with obesity, ages 10-18 years old. Subjects will be randomized to receive intranasal oxytocin or placebo (1 spray per nostril, 4 times per day) for 12 weeks. Study visits include screening to determine eligibility, 2-part main study visits at baseline, week 8, and week 12, and safety check-in visits at weeks 1, and 4; phone calls at weeks 2, 6, and 10, with a safety follow-up visit 6 weeks after the last dose of study drug. Study procedures include appetite, behavioral, metabolic, and endocrine assessments.

Participants needed: 55
Trial details
Phase: Phase 2Age: 10-18Biological sex: AllType: InterventionalSponsor: Massachusetts General HospitalUpdated: Jun 26, 2026Locations: 1
Eligibility criteria

Males and Females, 10-18 years [+2]

Current substance abuse [+16]

Status: Recruiting

Mindfulness and Meditation Based Lactation Education on Maternal Breastmilk in the Neonatal ICU

The purpose of this research is to investigate associations between mindfulness and meditation techniques and changes in maternal breastmilk in the mother pumping for her NICU infant.

Participants needed: 40
Trial details
Age: 20+Biological sex: FemaleType: InterventionalSponsor: Mayo ClinicUpdated: Jan 20, 2026Locations: 1
Eligibility criteria

Maternal age > 20 years of age [+6]

Maternal extensive existing mindfulness practice [+5]

Status: Not yet recruiting

Comparing Intramyometrial Tranexamic Acid and Oxytocin for Blood Loss in Cesarean Section

Cesarean section is the most prevalent operation among women globally, 10-15% (1, 2). Recent research has shown Egypt to be the third-largest country globally, with an estimated 52% cesarean sections (3). However, the cesarean section has many serious complications, including the primary postpartum hemorrhage (PPH) (4). During labor, the average blood loss is about 300 to 400 ml. Bleeding postpartum is known as losing over five hundred milliliter of blood following a vaginal birth and losing over one thousand milliliter after the cesarean section (5). The prime cause of maternal death rate is postpartum bleeding, predominately in poor countries, and the estimated mortality number due to postpartum bleeding is one hundred thousand per year (6). Therefore, it is essential to reduce bleeding during and after CS to diminish maternal mortality and morbidity (7). The most successful technique for decreasing PPH is the active third stage labor management, requiring prophylactic uterotonic drugs like oxytocin, ergometrine malate, prostaglandins (E1, E2, and F2α), and combinations of them, or hemostatic agent as tranexamic acid (Kapron) and Etamsylate (Dicynon) (8, 9).

Participants needed: 150
Trial details
Phase: Phase 3Age: 20-40Biological sex: FemaleType: InterventionalSponsor: Cairo UniversityUpdated: Sep 5, 2024Locations: 1
Eligibility criteria

Women booked for a primary elective cesarean section, not in active labor [+7]

Placenta previa. [+11]